Clinical Trials

This page contains information on clinical trials at the Division of Neurosurgery.

We are at the forefront of neurosurgical innovation through our commitment to clinical trials. These trials are essential for advancing our understanding of neurological disorders and developing new surgical techniques and tools. Our multidisciplinary teams work collaboratively to ensure the highest ethical and scientific standards, aiming to translate research findings into improved patient care. Participation in our clinical trials offers patients access to cutting-edge treatments while contributing to the future of neurosurgery.

Actively recruiting trials

EMBRI

  •  Full name: Electrocorticographic Monitoring of Brain Retraction Injury
  •  Key inclusion criteria: Patients having neurosurgery involving brain retraction, able to self consent
  •  Contacts: Will Muirhead 

GOET

  •  Full name: Genetics of Endocrine Tumours
  •  Key inclusion criteria: Patients with endocrine tumors and controls
  •  Contacts: Hani Marcus 

High-throughput Mapping of Neural Circuitry and Gene Expression in the Human Brain

  •  Key inclusion criteria: Patients undergoing open brain surgery with resection of brain tissue
  •  Contacts: Ciaran Hill

Mechanisms of Glioma Invasion

  • Sub-studies: 1. Understanding effect of neuronal/injury responses on glioma behavior; 2. Defining the Invasive Margin with Hyperspectral Imaging
  • Key inclusion criteria: Patients undergoing resection of a presumed Glioma.
  • Contacts: Ciaran Hill 

MIST

  • Full name: Markers of delayed cerebral ischemia and hydrocephalus trial
  • Key inclusion criteria: Aneurysmal SAH patients that require EVD or LD insertion
  • Contacts: Ahmed Toma, Lucia Darie 

MODIC

  • Key inclusion criteria: Adult patients with chronic low back pain > 6 months associated with Modic 1 +/-2 changes, at a single lumbar level. Failure of standard of care therapies.
  • Contacts: Adrian Casey, Jim Greenwood
  • https://themodictrial.com/

OLFACTORY STEM CELLS 

  • Key inclusion criteria: Adult patients over the age of 18 who are undergoing trans-nasal surgery for accessing the pituitary gland or the anterior cranial fossa will be eligible to enter the study.
  • Contacts: Hani Marcus 

Op-TICS

  • Full name: Double blind comparison of optimised Deep Brain Stimulation for severe Tourette syndrome
  • Key inclusion criteria: Severe refractory GTS symptoms not responding to conventional treatment
  • Contacts: Patricia Limousin, Eileen Joyce, Ludvic Zrinzo
  • https://www.isrctn.com/ISRCTN17008820

ROAR

  • Full name: Risk of Aneurysm Rupture Study
  • Key inclusion criteria: Adult patients with intracranial intradural unruptured aneurysm confirmed on angiogram
  • Contacts: Patrick Grover
  • https://roarstudy.co.uk/

SCIL

  • Full name: Does Interleukin-1 Receptor Antagonist Improve Outcome Following Aneurysmal Subarachnoid Haemorrhage (aSAH)? A Phase III Trial
  • Key inclusion criteria: CT positive spontaneous SAH, within 72h of ictus
  • Contacts: Ahmed Toma, Tom Doke 
  • https://www.clinicaltrials.gov/study/NCT03249207

Opening soon

IIH IT

  • Full name: Idiopathic Intracranial Hypertension Intervention Trial
  • Contact: Emma Dalton, Fion Bremner 

POLYFIX-DCM

  • Full name: POsterior laminectomY with FIXation for Multilevel Degenerative Cervical Myelopathy
  • Contact: David Choi, Sid Vankipuram
  • https://polyfix-dcm.com/

RECEDE-DCM

STOP-EM

  •  Full name: Surgeons Trial Of Prophylaxis for Epilepsy in seizure naive patients with Meningioma: a randomised controlled trial
  •  Contact: Hani Marcus

SUNAN

  • Full name: Single Unit Neurophysiological Architecture of the Neocortex
  • Contact: Will Muirhead

If you have trials you would like to include please email: ciaran.hill@nhs.net